Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
It does not appear to affect IGF-1 levels or insulin levels and therefore is not a risk factor in promoting glucose intolerance or diabetes
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Future research should focus on refining these treatment modalities and expanding comparative studies to optimize B12 deficiency management strategies effectively
Statistically non-significant, clinically uninteresting
Changes to the treatment plan are made based on these checks to help patients get the best results
US$ 24.55
US$ 29.90
US$ 22.12
US$ 25.00
US$ 23.69
US$ 20.60